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Abstract: Multiple myeloma (MM) has an inherent high risk of thromboembolic events associated
with patient as well as disease- and treatment-related factors. Previous studies have assessed the
association of MM-related thromboembolism using “traditional” Kaplan–Meier (KM) and/or Cox
proportional hazard (PH) regression. In the presence of high incidence of death, as would be the case
in cancer patients with advanced age, these statistical models will produce bias estimates. Instead, a
competing risk framework should be used. This study assessed the baseline patient demographic and
clinical characteristics associated with MM-related thromboembolism and compared the cumulative
incidence and the measures of association obtained using each statistical approach. The cumulative
incidence of thromboembolism was 9.2% using the competing risk framework and nearly 12% using
the KM approach. Bias in the measures of covariate risk associations was highest for factors related
to risk of death such as increased age (75% bias) and severe liver disease (50%) for the Cox PH model
compared to the competing risk model. These results show that correct specification of statistical
techniques can have a large impact on the results obtained.
Keywords: venous thromboembolism; multiple myeloma; competing risks
1. Introduction
Compared to the general population, individuals with cancer are at 4 to 7 times higher risk of
developing a venous thromboembolism (VTE) [1–4]. Malignancy induces a prothrombotic state which
includes activation of the coagulation cascade, increase in pro-inflammatory cytokines, as well as
inhibition of natural anticoagulants and is further exacerbated by cancer treatment and surgery [5–7].
Other risk factors for VTE in cancer include the site and stage of the tumor, older age, prior history
of clots, and comorbidities [6,8–10]. Although at an already increased risk of death from cancer, VTE
carries a substantial risk of mortality with clotting events accounting for up to 10% of all deaths in
patients with cancer [11–13].
Multiple myeloma (MM) has one of the highest risks of thrombosis among all cancers due to
disease-related pathological changes and treatment [7,14]. Thalidomide and lenalidomide (IMIDs) are
well known to be associated with increased risk of thrombosis [15], especially when combined with
high-dose steroids and other chemotherapy, with incidence approaching 25% in some studies [16–19].
Other common MM treatments include proteasome inhibitors (PIs; bortezomib, carfilzomib) and
cytotoxic therapies (cyclophosphamide, melphalan, others), which have been shown to have a lower,
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though still increased, risk of VTE compared to IMIDs [20]. Other disease-related factors with potential
to increase thrombotic risk include use of central venous catheters (CVC), erythropoietin agents,
hospitalization, and infection [6,10,21–26]. Due to this inherent increased risk of thrombosis with
MM, guidelines U.S. guidelines recommend routine thromboprophylaxis with low-molecular weight
heparins (LMWH) or aspirin [27,28].
These previous studies have assessed VTE risk in MM during randomized-controlled trials
(RCTs) comparing alternative treatment strategies or in small observational utilizing “traditional”
Kaplan–Meier and/or Cox proportional hazard models. In these statistical frameworks, death is
considered a censoring event. This violates a basic assumption that censoring events and the outcome
of interest must be independent of each other, meaning that censoring is uninformative. However,
given that the occurrence of death prevents the outcome from ever occurring, death competes with the
outcome and should not be considered a censoring event [29]. Instead, a competing risks framework
should be used which treats death as a separate outcome. A study by Ay et al. [29] compared traditional
methods to competing risk methods and found significant bias when ignoring death as a competing
risk with VTE incidence during cancer. They observed that the bias in the cumulative incidence
of thromboembolism is a function of the incidence of the competing risk. This study did not look
at individual factors that may be associated with thromboembolism and how estimates of relative
association may be impacted by these methods.
The objective of this study was to determine the one-year incidence of thrombotic events in
MM and to assess the association of baseline characteristics and thrombosis in these patients while
comparing traditional time-to-event methods with competing risk methods. This study compared
risk associations between the two statistical frameworks as applied to this specific cancer type and
calculated the bias that would be observed with “traditional” methods.
2. Materials and Methods
2.1. Data Source
This was a retrospective cohort study utilizing Truven Health Analytics MarketScan Commercial
Claims and Encounters and Medicare Supplemental databases during the years 2008–2013. The
MarketScan data are administrative claims data including medical diagnostic and procedural billing
information and pharmacy fill records for those with commercial insurance linked to demographic
and insurance enrollment information for each individual. The data include information regarding
medical encounters for nearly 40 million persons each year and are representative of the commercially
insured population in the U.S.
2.2. Patient Inclusion
We included patients with at least two separate claims with a diagnosis of MM (ICD-9: 203.0x) at
least 14 days apart. For further inclusion, subjects were required to have a minimum of 6 months of
continuous medical and pharmacy insurance coverage prior to the first MM diagnosis and be at least
18 years or older at diagnosis. Subjects also could not have a previous diagnosis of another cancer or a
thrombotic outcome event during the 6-month, pre-index period.
2.3. Subject Characteristics
Age was assessed on the MM index date and gender was linked from the enrollment file. The
Charlson Comorbidity Index was used to assess comorbidity burden based on the ICD-9-CM coding
algorithm [30] and the total score was further categorized by 0, 1–2, 3–4, and 5+ groups with individual
comorbidities also reported. Additional comorbidities of interest were also assessed during the 6 month
pre-index period, including thrombocytosis (ICD-9: 238.71, 289.9), leukocytosis (ICD-9: 288.5), anemia
(ICD-9: 280.x–285.x), obesity (ICD-9: 278.01–278.03, V85.3, V85.4), hypocoagulopathies (ICD-9: 286.x)
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hypercoagulopathies (ICD-9: 289.81–289.82), thrombocytopenia (ICD-9: 238.71, 289.9), and leukopenia
(ICD-9: 288.5x).
2.4. Outcome Events
DVT and PE events were assessed based on previously published ICD-9-CM algorithms [31–33].
PVT was identified by ICD-9-CM code 452.x and AT identified by ICD-9-CM code 444.x. Date of death
was based on discharge status codes on hospital or hospice records and loss to follow-up occurred
when continuous insurance coverage ended during the follow-up period or follow-up terminated at
the end of the data (December 2013). All other individuals were censored after one year of follow-up.
If a thrombosis occurred on the same day as death, the event was recorded as the thrombosis as it was
the main outcome of interest in this study. Subjects were followed until one of the following occurred:
(1) a thrombosis event; (2) death; (3) loss to follow-up; or (4) end of the 1 year study period.
2.5. Survival Analysis
Person time was calculated correcting for the differential follow-up of each subject. The incidence
rate of thrombosis was reported as the rate per 1000 person-years. The association of thrombosis with
baseline demographic and clinical characteristics at diagnosis was assessed using a competing risks
regression model. In this model the dependent outcome has three levels, 0 = censored, 1 = thrombosis,
and 2 = death. Subdistribution hazard ratios (HR) and their 95% confidence intervals (CI) for the
association between each baseline covariate and thrombotic events were estimated for each baseline
covariate included in the model. For demonstration of the selection of statistical methods, a Cox
proportional hazard (PH) model was also constructed wherein death was considered a censoring event
and not a competing risk and included the same specification as the competing risks model. Bias of the
Cox PH model HRs was calculated as the relative difference between the Cox HR and the competing
risk HR and is reported as the percent bias. The one-year cumulative incidence of thrombotic events
was reported for the total cohort by the Fine and Gray method for competing risks. One minus the
Kaplan–Meier estimate was used to plot the cumulative probability of thromboembolism, ignoring
the competing risk of death. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary,
NC, USA). The University of Kentucky Institutional Review Board approved the use of the data for
this study.
3. Results
3.1. Incidence of Thrombosis
There were 1050 thrombosis events observed in 13,700 individuals during the one-year follow-up.
This included 756 DVTs (72% of events), 238 PEs (22.7%), 51 ATs (4.9%), and 5 PVTs (0.5%). Nearly
one-half (N = 520, 49.5% of events) occurred within the first 90 days after MM diagnosis. Table 1
includes the demographics and clinical characteristics of the cohort.
Table 1. Baseline characteristics of the cohort at diagnosis of multiple myeloma.
Overall Cohort
N = 13,700
Age Mean 63.9 SD 13.7
18–34 283 2.1
35–64 7389 53.9
65–74 2648 19.3
75+ 3380 24.7
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Table 1. Cont.
Overall Cohort
N = 13,700
Gender
Male 6625 48.4
Female 7075 51.6
Charlson Comorbidity Index Mean 1.1 SD 1.5
0 6892 50.3
1–2 4758 34.7
3–4 1476 10.8
5+ 574 4.2
Comorbidity
MI 251 1.8
CHF 933 6.8
PVD 841 6.1
Dementia 123 0.9
COPD 1817 13.3
Rheumatism 734 5.4
PUD 134 1.0
Mild liver disease 551 4.0
Diabetes 2814 20.5
Diabetes with complications 755 5.5
Paralysis 68 0.5
Renal disease 1826 13.3
Severe liver disease 45 0.3
CVD 910 6.6
HIV/AIDS 30 0.2
Hypertension 6466 47.2
CHD 1725 12.6
Lipids 4260 31.1
High platelets 70 0.5
High white cell 270 2.0
Anemia 3727 27.2
Obesity 491 3.6
Hypocoagulopathies 544 4.0
Thrombocytopenia 363 2.7
Low white cell 237 1.7
Year of Diagnosis
2009 2469 18.0
2010 2476 18.1
2011 3153 23.0
2012 3053 22.3
2013 2549 18.6
CHF = congestive heart failure; PVD = peripheral vascular diseases; COPD = chronic obstructive pulmonary
disease; PUD = peptic ulcer disease; CVD = cerebrovascular disease; CHD = coronary heart disease;
SD = standard deviation.
The cohort contributed 9791.4 person-years of follow-up time for a one-year incidence rate
of thrombosis of 107.2 (95% CI, 100.0–113.9) events per 1000 person-years. The highest incidence
of thrombosis was in the first 30 days, with 251 events and an incidence rate of 234.2 (95% CI,
206.5–264.5) per 1000 person-years. The rate of thrombotic events decreased over the 60, 90, and
180 day intervals: 196.6 (95% CI, 178.3–216.4), 171.7 (95% CI, 157.4–187.0), 140.1 (95% CI, 130.5–150.1),
per 1000 person-years, respectively, There were 384 deaths experienced as a competing risk and a total
of 479 deaths during the study period with an incidence rate of 48.9 (95% CI, 44.7–53.5) deaths per
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1000 person-years. The one-year cumulative incidence of thrombosis was 9.2% (95% CI, 8.7%–9.7%)
for the total cohort (Figure 1) in the competing risk framework. Additionally, Figure 1 shows that the
Kaplan–Meier method overestimates the cumulative incidence, which underlies the statistical models.Healthcar  2016, 4, 16 5 of 10 
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3.2. Survival Model Result
Table 2 demonstrates the bias introduced by using odels in the presence f competing
risks. The highest bias can be observed in factors that would hypothetically be more associated with
the omitted competing risk such as severe comorbidities and increasing age. For example, if competing
risks are omitted, a much stronger association is observed between the 75+ age group and VTE, which
represents a 75% bias over the competing risks estimate. Older age was associated with an increase in
the hazard of thrombosis for the 35–64 and 65–74 age groups compared to the 18–34 reference group
(Table 2). Female gender showed a protective effect with HR = 0.7 (95% CI, 0.7–0.8) compared to
males. Increasing comorbidity bur en had no impact on the hazard of thrombosis at ba line; however,
some in ividual comorbi ities at baseline did increase the risk. Those with CHF had 70% higher
hazard (HR = 1.7 (95% CI, 1.4–2.1)) and th se it hypertension had 20% higher hazard (HR = 1.2
(95% CI, 1.0–1.3)). Diagnosis with both leukocytosis (HR = 1.3 (95% CI, 1.0–1.9)) and leukopenia
(HR = 1.6 (95% CI, 1.1–2.2)) had increased hazard of thrombosis in this population. There were no
other significant associations observed for the other included covariates.
Table 2. Results of competing risks model compared to the Cox PH model.
Competing Risks Cox PH
Covariate sHR 95% CI HR 95% CI % Bias
Age
18–34 Ref. Ref. Ref. Ref. Ref. Ref.
* 35–64 1.7 1.0 3.0 2.2 1.3 3.7 29.4%
* 65–74 1.9 1.1 3.2 2.4 1.4 4.1 26.3%
75+ 1.6 0.9 2.7 2.8 1.6 4.8 75.0%
Gender
Male Ref. Ref. Ref. Ref. Ref. Ref.
* Female 0.7 0.7 0.8 0.7 0.7 0.8 0.0%
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Table 2. Cont.
Competing Risks Cox PH
Covariate sHR 95% CI HR 95% CI % Bias
Charlson Comorbidity Index
0 Ref. Ref. Ref. Ref. Ref. Ref.
1–2 1.0 0.5 2.1 1.0 0.8 1.2 0.0%
3–4 0.8 0.5 1.3 0.8 0.6 1.2 0.0%
5+ 1.0 0.8 1.2 0.9 0.5 1.7 ´10.0%
Comorbidities
MI 0.9 0.6 1.4 1.1 0.8 1.5 22.2%
* CHF 1.7 1.4 2.1 1.9 1.6 2.3 11.8%
PVD 1.2 0.9 1.5 1.2 1.0 1.4 0.0%
Dementia 1.2 0.7 2.1 1.5 0.9 2.3 25.0%
COPD 0.9 0.8 1.1 1.1 0.9 1.3 22.2%
Rheumatism 0.9 0.6 1.2 0.7 0.5 1.0 ´22.2%
PUD 0.8 0.5 1.5 1.0 0.7 1.6 25.0%
Mild liver disease 0.8 0.5 1.1 0.9 0.7 1.2 12.5%
Diabetes 1.0 0.8 1.2 1.1 0.9 1.2 10.0%
Diabetes with complications 1.1 0.8 1.5 1.0 0.7 1.3 ´9.1%
Paralysis 1.4 0.8 2.5 1.2 0.7 2.0 ´14.3%
Renal disease 1.0 0.8 1.3 1.0 0.8 1.3 0.0%
Severe liver disease 1.1 0.4 3.0 1.7 0.9 3.4 54.5%
CVD 1.0 0.8 1.3 1.1 0.9 1.4 10.0%
* Hypertension 1.2 1.0 1.3 1.1 1.0 1.3 ´8.3%
CHD 1.0 0.8 1.1 1.0 0.9 1.1 0.0%
Lipids 1.0 0.9 1.1 1.0 0.9 1.1 0.0%
High platelets 1.0 0.5 2.1 1.0 0.5 1.8 0.0%
* High white cell 1.3 1.0 1.9 1.2 0.9 1.6 ´7.7%
Anemia 0.9 0.8 1.1 1.0 0.9 1.6 11.1%
Obesity 1.2 0.9 1.6 1.1 0.9 1.4 ´8.3%
Hypocoagulopathies 0.9 0.6 1.4 0.8 0.6 1.3 ´11.1%
Thrombocytopenia 1.0 0.6 1.8 1.2 0.8 2.0 20.0%
* Low white cell 1.6 1.1 2.2 1.4 1.0 1.9 ´12.5%
sHR = subdistribution hazard ratio; CI = confidence interval; MI = myocardial infarction; CHF = congestive
heart failure; PUD = peptic ulcer disease; CVD = cerebrovascular disease; CHD = coronary heart disease;
Ref. = Reference category;* p < 0.05.
4. Discussion
Treatment advances over the last decade for MM have led to an increase in median survival
greater than 5 years [34,35]. However, thrombotic complications have emerged as serious adverse
effects of treatment driving the consideration of thromboprophylaxis in guidelines and RCTs in
this patient population [36,37]. Despite the known risk, the pathogenesis of thrombosis in MM is
poorly understood due to the various factors that can impart risk including patient characteristics,
disease-related factors, as well as treatment-related risks [7]. Although thrombotic events have not
been shown to have a large impact on overall survival specifically in MM [36], thrombosis events can
cause interruption in therapy as well as tremendous economic and humanistic burdens in the MM
population [38,39]. Recent American Society of Clinical Oncology guidelines have called for better
evidence regarding the increased risk of thrombosis and MM so that prevention efforts can be focused
towards periods of highest risk [40].
This study investigated two statistical approaches to assess the baseline factors related to
thrombosis risk in newly diagnosed MM. For this population the competing risk of death is a
contribution by many factors, including the advanced age of the cohort, having cancer, as well
as the risk of death from the other outcome events [30]. The primary model used a competing
risks framework, given that the outcome events cannot be considered independent of each other, i.e.
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experiencing one may preclude experiencing another or one event may cause another. Failure to do so
can overestimate survival for traditional Kaplan–Meier or proportional hazard based analyses and
lead to inflated cumulative incidence functions and biased associations [30]. In this study, this would
have overestimated the cumulative incidence to be nearly 12% over the one-year study period. For
measures of association in the regression models, the largest bias was observed for those factors that
would be more highly associated with the competing risk. For example, age 75 and older had a HR of
2.8 (95% CI 1.6–4.8) in the Cox PH model. This is compared to the “true” value from the competing
risk model of 1.6 (0.9–2.7)—a relative bias of 75%. Likewise, there was significant bias associated with
liver disease (54.5%), dementia (25.0%), peptic ulcer disease (25.0%), and chronic pulmonary disease
(25.0%). More importantly, as in the case of increasing age and peripheral vascular disease, the bias
alters the bounds of the confidence interval to include the null making the interpretation of the findings
more tedious.
In the primary analysis, there were few baseline factors found to be associated with risk in
this study suggesting that risk may be associated with factors related to treatment of MM instead
of pre-existing, patient-related factors. We observed that nearly one-half of all thrombotic events
occurred within the first 90 days after MM diagnosis. A similar finding has been found by other
studies, suggesting that the risk in the initial stage of diagnosis and treatment may be related
to high tumor burden and release of thrombogenic factors with initiation of treatment [16,41,42].
This underscores the need to identify early risk factors at diagnosis to guide the utilization of
thromboprophylaxis—especially in the first 90 days of treatment. In a post-hoc analysis restricting
events to the first 90 days and in the full model analysis presented here, however, we found few
demographic or clinical characteristics that were predictive of outcome events. This suggests that
thrombosis risk in this population may be primarily driven by treatment and not necessarily any
underlying risk.
Due to the methodological focus and goals of this study, we ignored other factors related
to VTE risk in multiple myeloma—mainly chemotherapeutic agents used and utilization of
anticoagulant/antiplatelet therapy. It is well known that IMID therapy is associated with a large
increase in risk and has led to thromboprophylaxis being commonplace for these patients. Treatment is,
by nature, highly time-variant, given ever-changing treatment regimens as well as periods of treatment
interspersed with periods of no treatment. This implies the usefulness of time-varying statistical
frameworks and represents one of the primary limitations of competing risks analyses, given that
competing risks methods are not compatible with time-varying covariates. While it is beyond the
scope of this study to address time-varying exposures, we have shown the bias introduced when
ignoring competing risks. Thus, there is a tenuous balance between including biased estimates of the
survival functions or excluding time-varying covariates. Other methodologies can be utilized as well,
such as the case-crossover or case-time-control study designs which avoid these setbacks. This study
is subject to several limitations inherent to claims-based studies [43,44]. This study relied on ICD-9
coding available in the claims to diagnose study subjects with outcome events and comorbidities. It is
impossible to confirm a positive diagnosis using these data; however, claims-based coding algorithms
for VTE have been shown to perform strongly especially when there is a high risk of VTE in the
population [32,45]. Further, information regarding MM severity and staging is not available in claims
data and, thus, could not be included here. Likewise, medications not obtained using insurance,
such as over-the-counter aspirin for thromboprophylaxis, cannot be observed in claims data and was
unobserved in this study [46].
5. Conclusions
This study used a competing risks framework given that the outcome events cannot be considered
independent of each other, i.e., experiencing one may preclude experiencing another or one event may
cause another. Failure to do so can overestimate survival for traditional Kaplan–Meier or proportional
hazard based analyses and lead to inflated cumulative incidence functions and biased associations.
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In this study, this would have overestimated the cumulative incidence to be nearly 12% over the
one-year study period. For this population the competing risk of death is a contribution by many
factors including the advanced age of the cohort, having cancer, as well as the risk of death from the
other outcome events. Death must be accounted for in older populations as well as in high mortality
disease states when the incidence of death is high to avoid potential statistical pitfalls of traditional
Kaplan–Meier and Cox PH methods.
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LMWH low-molecular weight heparin
RCT randomized controlled trial
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